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Background
It is unclear whether there is a clinically signiﬁ cant 
advantage to prophylactic low-molecular-weight heparin 
(LMWH) versus unfractionated heparin (UFH) in mixed 
medical/surgical critically ill adult patients.
Methods
Objective: To compare once daily dalteparin with twice 
daily unfractionated heparin for primary prophylaxis of 
proximal deep venous thrombosis in critically ill adults.
Design: A superiority randomized double-blinded con-
trolled trial from 2006 to 2010 in both medical and 
surgical ICUs. (ClinicalTrials.gov registration number: 
NCT00182143)
Setting: Multi-center, international medical and surgical 
intensive care units (ICUs)
Subjects: Critically ill adults expected to remain in the 
ICU for at least 3 days.
Intervention: Patients were randomized to either twice 
daily UFH or daily dalteparin for the duration of ICU 
admission.
Outcomes: Th e primary endpoint was proximal leg deep 
venous thrombosis (DVT), at least three days after 
randomization, detected on twice weekly screening 
ultrasound. Secondary endpoints were: any DVT, pulmo-
nary embolism (PE), venous thromboembolism (VTE), 
death, heparin-induced thrombocytopenia (HIT), major 
bleeding, and composite death/VTE.
Results
Th ree thousand seven hundred and forty-six subjects 
were included in the intention-to-treat analysis. Proximal 
leg DVT occurred in 96 of 1873 (5.1%) patients 
randomized to dalteparin versus 109 of 1873 (5.8%) 
patients randomized to UFH (hazard ratio in the 
dalteparin group, 0.92; 95% conﬁ dence interval [CI], 0.68 
to 1.23; P  =  0.57). Th e incidence of PE was 1.3% in the 
dalteparin group compared to 2.3% in the UFH group 
(hazard ratio, 0.51; 95% CI, 0.30 to 0.88; P = 0.01). Th ere 
was no mortality diﬀ erence and no diﬀ erence in major 
bleeding between the two study arms. Th ere was a 
statistically signiﬁ cant decrease in incidence of HIT in 
the dalteparin group in the per-protocol analysis, but not 
in the intention-to-treat analysis.
Limitations
Comparing the incidence of PE was a secondary endpoint 
and the study was not appropriately powered for this 
conclusion.
Conclusions
Among critically ill adult patients, dalteparin was not 
superior to UFH at preventing proximal lower extremity 
DVTs. Th ere is a suggestion that dalteparin might be 
superior to UFH at preventing pulmonary embolism but 
a larger trial is necessary to conﬁ rm this result.
Commentary
Venous thromboembolism (VTE) is a signiﬁ cant cause of 
morbidity and mortality [1] and critically ill patients are 
at a higher risk [2] of developing deep venous thrombosis 
(DVT) and pulmonary thromboembolism (PE) compared 
to non-critically ill patients. Low molecular weight 
heparin (LMWH) has shown superiority and is recom-
mended over unfractionated heparin (UFH) in certain 
patient populations (such as trauma, spinal cord injury, 
and orthopedics [3]) but has not been well studied for 
general ICU patients. Th ere have been four randomized 
studies of VTE prophylaxis in critically patients [4-7]. 
Th ese studies showed decreased VTE with UFH and 
LMWH prophylaxis compared to placebo, but were 
underpowered to determine superiority of LMWH 
versus UFH. Th e PROTECT study was the largest study © 2010 BioMed Central Ltd
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to date comparing LMWH to UFH prophylaxis in general 
ICU patients.
PROTECT was a multi-center, randomized, double 
blinded prospective trial which enrolled adult general 
intensive care unit (ICU) patients who were expected to 
have an ICU length of stay greater than 3 days. Th e 
primary endpoint was proximal lower extremity DVT 
detected on twice weekly screening ultrasound. Secon-
dary endpoints included any DVT, PE, VTE, death, 
heparin-induced thrombocytopenia, major bleeding, and 
composite of death/VTE. Th e study was designed to 
detect a 30% relative risk reduction of proximal leg DVT 
in the dalteparin arm compared to the UFH arm 
assuming a control arm incidence of 9% [8]. Th e study 
failed to show a 30% relative risk reduction in rates of 
proximal leg DVT in the dalteparin (5.1%) group 
compared to the UFH (5.8%) group. Th e incidence of PE 
was 2.3% in the UFH group compared to 1.3% in the 
dalteparin group (hazard ratio, 0.51; 95% CI, 0.30 to 0.88; 
P = 0.01).
Strengths of this trial include multicenter recruitment, 
intention-to-treat analysis and randomized double blind 
design. Th e authors conducted a pilot trial of 128 patients 
[8] before commencing the main trial. Because of slow 
recruitment in the pilot trail, the authors trimmed 
PROTECT’s exclusion criteria: they included all renal 
failure patients regardless of estimated glomerular 
ﬁ ltration rate and included more patients with thrombo-
cytopenia. Th ese changes broadened the study group and 
made the PROTECT’s results more generalizable.
Despite being a very large study, PROTECT may have 
needed more subjects to reveal a statistically signiﬁ cant 
reduction of DVTs. PROTECT’s control arm event rate 
was less than the one used in the power calculation which 
may have underpowered the trial. Th e study failed to 
reject the primary null hypothesis and could not exclude 
a 32% beneﬁ t or a 23% harm associated with dalteparin 
versus UFH. Even though the incidence of DVT was 
similar in both arms, the study had a superiority design 
and therefore, we should not conclude non-inferiority 
between the two groups. Th e statistically signiﬁ cant 
reduction in incidence of PE must be taken with caution 
because this was a secondary endpoint and applying the 
results of a secondary endpoint to a general patient 
population has inherent uncertainty [9]. Furthermore, it 
is diﬃ  cult to determine the clinical signiﬁ cance of a 1% 
reduction of PE without a reduced rate of proximal DVT 
or reduced mortality.
Th e PROTECT trial was negative for the primary 
endpoint of proximal DVT but does provide us with the 
best evidence to date regarding LMWH versus UFH for 
critically ill adults. No ﬁ rm conclusions can be drawn 
from PROTECT even though there is a hint dalteparin 
might be superior to UFH (lower rates of PE and heparin-
induced thrombocytopenia), but the data are just not 
robust enough to answer those questions.
Recommendation
Th e PROTECT study is the best data to date comparing 
LMWH to UFH for primary prophylaxis of proximal leg 
DVT in critically ill adult patients. Th ere is no conclusive 
evidence supporting the use of dalteparin in lieu of UFH; 
however, dalteparin appears to be a safe alternative to 
UFH for VTE prophylaxis in general ICU patients. We 
would recommend dalteparin over UFH if overall 
healthcare costs were similar or lower.
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